口服用グルタミン酸カルボキシペプチダゼII阻害剤としてのプロドラッグ (2-Phosphonomethyl) ペンタンジオ酸 (2-PMPA)
Niyada Hin1,2, Chae Bin Lee1,2, Sadakatali Gori1,2
1Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ACS medicinal chemistry letters
|August 29, 2025
まとめ
新たに開発された2 - フォスフォノメチル - ペンタンジオ酸 (2-PMPA) の新薬は,その経口投与を強化する. サイクロサルベースの前薬は,マウスの口服後にプラズマに2- PMPAのマイクロモラーレベルを効果的に提供します.
科学分野:
- 薬剤化学
- 薬理学について
- 薬物の配達
背景:
- 2- フォスフォノメチル) ペンタンジオ酸 (2- PMPA) はグルタミン酸カルボキシペプチダースII (GCPII) の強力な阻害剤である.
- 2 - PMPAの酸性グループによる口腔での生物利用性が低いため,治療用途が制限されています.
- トリス-POC-2-PMPAとテトラ-ODOL-2-PMPAのような前薬戦略は,経口吸収の改善に有望であることが示されています.
研究 の 目的:
- ProTide と cycloSal のプロモエイトを用いて,2- PMPA の新薬前薬戦略を探求する.
- 2- PMPAの脂性および経口生物利用性を高めるため
- 新しい前薬の有効性を in vivo で評価する.
主な方法:
- プロトイドとサイクロサルのグループとカルボキシラートのエステル群による2 - PMPA前薬の合成
- ネズミに合成された前薬の経口投与
- 検証された分析方法を用いてマウスの血における2-PMPA濃度の定量化
主要な成果:
- いくつかのサイクロサル基の2-PMPA前薬が成功して合成された.
- これらの前薬の経口投与は,2- PMPAの検出可能な血濃度をもたらした.
- 2- PMPAのマイクロモラー濃度は,特定のサイクロサール前薬で得られた.
結論:
- サイクロサルベースの前薬は,2- PMPAの経口投与のための有効な戦略です.
- これらの前薬は,2- PMPAの生物学的利用可能性の制限を克服することができます.
- サイクロサルの前薬のさらなる開発は,GCPII阻害剤の改善された治療用途につながる可能性があります.
関連する概念動画
Prodrugs
2.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.8K
Antiepileptic Drugs: Glutamate Antagonists
511
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
511
Drug Metabolism: Phase II Reactions
4.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Phase II Reactions: Acetylation Reactions
347
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
347


